VistaGen Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From VistaGen Therapeutics, Inc.
Plus deals involving Astellas/Menarini, Maruho/Fortress Biotech, Zenas/Bristol Myers Squibb, Huadong Medicine/MC2 and more.
CEO Shawn Singh discusses path forward for fasedienol (PH94B) using the classic LSAS primary endpoint in next clinical trial. Pherine nasal spray candidate failed to meet the primary endpoint (the patient-reported SUDS) in its first pivotal Phase III study, whose design was constrained by the Covid pandemic.
Mersana signs its third ADC partnership with big pharmas for the year with Merck agreement. Lilly expands its RNA editing partnership with ProQR, which now has the potential to earn an additional $2.5bn. Novartis continues its divestment efforts in deals with Harrow, Erasca.
Failure of pherine nasal spray candidate in first of two Phase III trials for social anxiety disorder puts program in doubt, while the California biotech’s share price craters.
- Research, Analytical Equipment & Supplies
- Drug Discovery Technologies
- Gene Therapy, Cell Therapy
Drug Discovery Technologies
- Other Names / Subsidiaries
- VistaStem Therapeutics, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.